Novo Nordisk's Stock Hinges on ADA Data as US Reimbursement Window Narrows

The Danish pharmaceutical giant enters June fighting on two fronts. In New Orleans, it will unfurl the next generation of its metabolic pipeline at the American Diabetes Association's Scientific Sessions from 5 to 8 June. At home in the US, however, the commercial terrain is shifting: a key insurance advantage for Wegovy is about to disappear.

Novo Nordisk plans to present 40 abstracts at the conference, with the spotlight falling on the REIMAGINE phase 3 programme for CagriSema. The fixed-dose combination pairs a long-acting amylin analogue with semaglutide, and data will show how well it improves blood sugar control and body weight in patients with type 2 diabetes on various background therapies. A dedicated symposium on 7 June will discuss those results.

Alongside CagriSema, phase 2b data for zenagamtide — formerly known as Amycretin — will be unveiled. This injectable molecule simultaneously targets GLP-1 and amylin receptors, aiming to go beyond conventional GLP-1 therapies. Both candidates remain unapproved in the US, a caveat Novo Nordisk itself emphasises.

The company has scheduled a separate R&D investor day on the same day, 7 June, to provide additional commentary on the conference data. That gives the date a double significance: clinical substance and capital markets communication in one sitting.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Beyond the main events, the abstract programme covers semaglutide in cardiovascular, renal and pulmonary indications — including asthma, sleep apnoea and MASH — as well as insulin Icodec and the once-weekly IcoSema. The broader message is that the GLP-1 franchise extends well beyond weight loss, a narrative the company badly needs to reinforce given the mounting pricing pressure at home.

That pressure crystallised in a decision by CVS Caremark. The pharmacy benefits manager is ending Wegovy's exclusive preferred status on its formularies. Wegovy will remain on a preferred tier, but from 1 June Lilly's oral therapy Foundayo gains access, and Zepbound is set to follow on 1 October. Novo Nordisk will then compete with Lilly on the same insurance tier, eroding a commercial edge that had supported Wegovy through 2025.

Such formulary changes are more than technicalities. In the US market, they often determine which drugs remain affordable for patients. For Novo Nordisk, the move strikes at the distribution core of its most important growth product.

The stock reflects the nervous outlook. Shares changed hands at around €39.05, near flat on the day, though the 30-day return stands at plus 13%. Since the start of 2025, however, the equity has lost 12.6%, and over 12 months the decline deepens to 35.8%. The stock currently trades roughly 45% below its 52-week high, though it has recovered about 27% from the March trough.

Valuation tells a similar story of tempered expectations. The price-to-earnings ratio sits at about 10, well below both the five-year average of 27 and the sector median of 24. That discount prices in not only slower momentum but also downward revisions and the arrival of cheaper alternatives for older GLP-1 products.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

In a defensive move, Novo Nordisk has launched a savings programme for Ozempic in Canada, targeting eligible patients without public or private coverage. The aim is to bring the branded drug's cost closer to that of emerging generics.

Between 5 and 8 June, the question is whether CagriSema and zenagamtide can deliver enough clinical differentiation to persuade investors that the pipeline remains a credible growth engine. If the data are compelling, the depressed valuation gains a solid counterweight. If they are merely adequate, the dominant narratives will remain CVS, Lilly and generic erosion.

Ad

Novo Nordisk Stock: New Analysis - 29 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69443768 |